JP2008517032A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008517032A5 JP2008517032A5 JP2007537263A JP2007537263A JP2008517032A5 JP 2008517032 A5 JP2008517032 A5 JP 2008517032A5 JP 2007537263 A JP2007537263 A JP 2007537263A JP 2007537263 A JP2007537263 A JP 2007537263A JP 2008517032 A5 JP2008517032 A5 JP 2008517032A5
- Authority
- JP
- Japan
- Prior art keywords
- bicyclo
- octane
- methyl
- diaza
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 21
- 201000010099 disease Diseases 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- -1 selenophenyl Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 4
- 125000002971 oxazolyl group Chemical group 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 125000004952 trihaloalkoxy group Chemical group 0.000 claims 4
- 125000004385 trihaloalkyl group Chemical group 0.000 claims 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 230000006735 deficit Effects 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000004306 triazinyl group Chemical group 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- QRCGAJXDQNYPMX-UHFFFAOYSA-N 2-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-5-phenyl-1,3,4-thiadiazole Chemical compound CN1C(C2)CCC1CN2C(S1)=NN=C1C1=CC=CC=C1 QRCGAJXDQNYPMX-UHFFFAOYSA-N 0.000 claims 1
- YISXSTWECOJSAD-UHFFFAOYSA-N 2-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-5-phenyl-1,3-thiazole Chemical compound CN1C(C2)CCC1CC2C(S1)=NC=C1C1=CC=CC=C1 YISXSTWECOJSAD-UHFFFAOYSA-N 0.000 claims 1
- LHCADAWQIOZWDH-UHFFFAOYSA-N 2-[6-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)pyridazin-3-yl]aniline Chemical compound CN1C(C2)CCC1CN2C(N=N1)=CC=C1C1=CC=CC=C1N LHCADAWQIOZWDH-UHFFFAOYSA-N 0.000 claims 1
- WUSCINBBOHUBKL-UHFFFAOYSA-N 3-(5-thiophen-2-ylpyridin-2-yl)-8-azabicyclo[3.2.1]octane Chemical compound C1C(N2)CCC2CC1C(N=C1)=CC=C1C1=CC=CS1 WUSCINBBOHUBKL-UHFFFAOYSA-N 0.000 claims 1
- KEELKQCQWRDADH-UHFFFAOYSA-N 3-(5-thiophen-3-ylpyridin-2-yl)-8-azabicyclo[3.2.1]octane Chemical compound C1C(N2)CCC2CC1C(N=C1)=CC=C1C=1C=CSC=1 KEELKQCQWRDADH-UHFFFAOYSA-N 0.000 claims 1
- UQERIPBUTVPFMW-UHFFFAOYSA-N 3-(6-thiophen-2-ylpyridazin-3-yl)-8-azabicyclo[3.2.1]octane Chemical compound C1C(N2)CCC2CC1C(N=N1)=CC=C1C1=CC=CS1 UQERIPBUTVPFMW-UHFFFAOYSA-N 0.000 claims 1
- CEKSCQNRQATKLX-UHFFFAOYSA-N 3-(6-thiophen-3-ylpyridazin-3-yl)-8-azabicyclo[3.2.1]octane Chemical compound C1C(N2)CCC2CC1C(N=N1)=CC=C1C=1C=CSC=1 CEKSCQNRQATKLX-UHFFFAOYSA-N 0.000 claims 1
- RDWJMJFGEMAGPU-UHFFFAOYSA-N 3-[5-(2-chlorophenyl)pyridin-2-yl]-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CC2C(N=C1)=CC=C1C1=CC=CC=C1Cl RDWJMJFGEMAGPU-UHFFFAOYSA-N 0.000 claims 1
- OMOCGMRKVIWDNX-UHFFFAOYSA-N 3-[5-(2-fluorophenyl)pyridin-2-yl]-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CC2C(N=C1)=CC=C1C1=CC=CC=C1F OMOCGMRKVIWDNX-UHFFFAOYSA-N 0.000 claims 1
- IOJGWDHQADVSJB-UHFFFAOYSA-N 3-[5-(3-chlorophenyl)pyridin-2-yl]-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CC2C(N=C1)=CC=C1C1=CC=CC(Cl)=C1 IOJGWDHQADVSJB-UHFFFAOYSA-N 0.000 claims 1
- JFXVXKKGOUZCJR-UHFFFAOYSA-N 3-[5-(3-fluorophenyl)pyridin-2-yl]-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CC2C(N=C1)=CC=C1C1=CC=CC(F)=C1 JFXVXKKGOUZCJR-UHFFFAOYSA-N 0.000 claims 1
- FEFZIEXFOPAJTI-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)pyridin-2-yl]-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CC2C(N=C1)=CC=C1C1=CC=C(Cl)C=C1 FEFZIEXFOPAJTI-UHFFFAOYSA-N 0.000 claims 1
- QTDHWMGAPMFAIO-UHFFFAOYSA-N 3-[5-(4-fluorophenyl)pyridin-2-yl]-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CC2C(N=C1)=CC=C1C1=CC=C(F)C=C1 QTDHWMGAPMFAIO-UHFFFAOYSA-N 0.000 claims 1
- GVBAMWCXJXPLCH-UHFFFAOYSA-N 3-[5-(furan-2-yl)pyridin-2-yl]-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CC2C(N=C1)=CC=C1C1=CC=CO1 GVBAMWCXJXPLCH-UHFFFAOYSA-N 0.000 claims 1
- DVYUXPSMWXNCQQ-UHFFFAOYSA-N 3-[5-(furan-3-yl)pyridin-2-yl]-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CC2C(N=C1)=CC=C1C=1C=COC=1 DVYUXPSMWXNCQQ-UHFFFAOYSA-N 0.000 claims 1
- XBOLMJAIWSSQIB-UHFFFAOYSA-N 3-[6-(2-chlorophenyl)pyridazin-3-yl]-8-methyl-3,8-diazabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CN2C(N=N1)=CC=C1C1=CC=CC=C1Cl XBOLMJAIWSSQIB-UHFFFAOYSA-N 0.000 claims 1
- KMZPCIDWXCUCPD-UHFFFAOYSA-N 3-[6-(2-fluorophenyl)pyridazin-3-yl]-8-methyl-3,8-diazabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CN2C(N=N1)=CC=C1C1=CC=CC=C1F KMZPCIDWXCUCPD-UHFFFAOYSA-N 0.000 claims 1
- TXFIHWUHZJMBHM-UHFFFAOYSA-N 3-[6-(2-methoxyphenyl)pyridazin-3-yl]-8-methyl-3,8-diazabicyclo[3.2.1]octane Chemical compound COC1=CC=CC=C1C1=CC=C(N2CC3CCC(N3C)C2)N=N1 TXFIHWUHZJMBHM-UHFFFAOYSA-N 0.000 claims 1
- IGBGHVHQEYSYQF-UHFFFAOYSA-N 3-[6-(3-chlorophenyl)pyridazin-3-yl]-8-methyl-3,8-diazabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CN2C(N=N1)=CC=C1C1=CC=CC(Cl)=C1 IGBGHVHQEYSYQF-UHFFFAOYSA-N 0.000 claims 1
- LOVITCACDLOTGT-UHFFFAOYSA-N 3-[6-(3-fluorophenyl)pyridazin-3-yl]-8-methyl-3,8-diazabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CN2C(N=N1)=CC=C1C1=CC=CC(F)=C1 LOVITCACDLOTGT-UHFFFAOYSA-N 0.000 claims 1
- IXCRJFKVIOQAAL-UHFFFAOYSA-N 3-[6-(3-methoxyphenyl)pyridazin-3-yl]-8-methyl-3,8-diazabicyclo[3.2.1]octane Chemical compound COC1=CC=CC(C=2N=NC(=CC=2)N2CC3CCC(N3C)C2)=C1 IXCRJFKVIOQAAL-UHFFFAOYSA-N 0.000 claims 1
- QTZOEHDPWANFNI-UHFFFAOYSA-N 3-[6-(4-chlorophenyl)pyridazin-3-yl]-8-methyl-3,8-diazabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CN2C(N=N1)=CC=C1C1=CC=C(Cl)C=C1 QTZOEHDPWANFNI-UHFFFAOYSA-N 0.000 claims 1
- MLCOLEAZHHTYBV-UHFFFAOYSA-N 3-[6-(4-fluorophenyl)pyridazin-3-yl]-8-methyl-3,8-diazabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CN2C(N=N1)=CC=C1C1=CC=C(F)C=C1 MLCOLEAZHHTYBV-UHFFFAOYSA-N 0.000 claims 1
- HMTDTAICRFCKHH-UHFFFAOYSA-N 3-[6-(4-methoxyphenyl)pyridazin-3-yl]-8-methyl-3,8-diazabicyclo[3.2.1]octane Chemical compound C1=CC(OC)=CC=C1C1=CC=C(N2CC3CCC(N3C)C2)N=N1 HMTDTAICRFCKHH-UHFFFAOYSA-N 0.000 claims 1
- KBAJSWABYPAQTG-UHFFFAOYSA-N 3-[6-(6-methoxynaphthalen-2-yl)pyridazin-3-yl]-8-methyl-3,8-diazabicyclo[3.2.1]octane Chemical compound C1C(N2C)CCC2CN1C(N=N1)=CC=C1C1=CC2=CC=C(OC)C=C2C=C1 KBAJSWABYPAQTG-UHFFFAOYSA-N 0.000 claims 1
- JCZLHZSIUDMYNL-UHFFFAOYSA-N 3-[6-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)pyridazin-3-yl]aniline Chemical compound CN1C(C2)CCC1CN2C(N=N1)=CC=C1C1=CC=CC(N)=C1 JCZLHZSIUDMYNL-UHFFFAOYSA-N 0.000 claims 1
- PWEZFKQNLWIPGJ-UHFFFAOYSA-N 3-[6-(furan-2-yl)pyridazin-3-yl]-8-azabicyclo[3.2.1]octane Chemical compound C1C(N2)CCC2CC1C(N=N1)=CC=C1C1=CC=CO1 PWEZFKQNLWIPGJ-UHFFFAOYSA-N 0.000 claims 1
- SUQCPEYDOLKQAL-UHFFFAOYSA-N 3-[6-(furan-2-yl)pyridazin-3-yl]-8-methyl-3,8-diazabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CN2C(N=N1)=CC=C1C1=CC=CO1 SUQCPEYDOLKQAL-UHFFFAOYSA-N 0.000 claims 1
- MGXGJGTTXATIJI-UHFFFAOYSA-N 3-[6-(furan-3-yl)pyridazin-3-yl]-8-azabicyclo[3.2.1]octane Chemical compound C1C(N2)CCC2CC1C(N=N1)=CC=C1C=1C=COC=1 MGXGJGTTXATIJI-UHFFFAOYSA-N 0.000 claims 1
- FHKSYHPBPDFISF-UHFFFAOYSA-N 3-[6-(furan-3-yl)pyridazin-3-yl]-8-methyl-3,8-diazabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CN2C(N=N1)=CC=C1C=1C=COC=1 FHKSYHPBPDFISF-UHFFFAOYSA-N 0.000 claims 1
- XUHXGBGWYUYLLC-UHFFFAOYSA-N 8-methyl-3-(2-phenylpyrimidin-4-yl)-8-azabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CC2C(N=1)=CC=NC=1C1=CC=CC=C1 XUHXGBGWYUYLLC-UHFFFAOYSA-N 0.000 claims 1
- JDWFMJUWVMBXAI-UHFFFAOYSA-N 8-methyl-3-(5-phenylpyrazin-2-yl)-8-azabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CC2C(N=C1)=CN=C1C1=CC=CC=C1 JDWFMJUWVMBXAI-UHFFFAOYSA-N 0.000 claims 1
- JRKBDTXDEZLYJQ-UHFFFAOYSA-N 8-methyl-3-(5-phenylpyridin-2-yl)-3,8-diazabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CN2C(N=C1)=CC=C1C1=CC=CC=C1 JRKBDTXDEZLYJQ-UHFFFAOYSA-N 0.000 claims 1
- ZLDUJUWZLYQFHQ-UHFFFAOYSA-N 8-methyl-3-(5-phenylpyrimidin-2-yl)-8-azabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CC2C(N=C1)=NC=C1C1=CC=CC=C1 ZLDUJUWZLYQFHQ-UHFFFAOYSA-N 0.000 claims 1
- DWQHUVLKWBYGRE-UHFFFAOYSA-N 8-methyl-3-(5-thiophen-2-ylpyridin-2-yl)-8-azabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CC2C(N=C1)=CC=C1C1=CC=CS1 DWQHUVLKWBYGRE-UHFFFAOYSA-N 0.000 claims 1
- NYQZOEBFIHJXQX-UHFFFAOYSA-N 8-methyl-3-(5-thiophen-3-ylpyridin-2-yl)-8-azabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CC2C(N=C1)=CC=C1C=1C=CSC=1 NYQZOEBFIHJXQX-UHFFFAOYSA-N 0.000 claims 1
- BEYZUTVKKFZHCP-UHFFFAOYSA-N 8-methyl-3-(6-phenylpyridin-2-yl)-3,8-diazabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CN2C(N=1)=CC=CC=1C1=CC=CC=C1 BEYZUTVKKFZHCP-UHFFFAOYSA-N 0.000 claims 1
- DOAQPGBYYNURQR-UHFFFAOYSA-N 8-methyl-3-(6-pyridin-3-ylpyridazin-3-yl)-3,8-diazabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CN2C(N=N1)=CC=C1C1=CC=CN=C1 DOAQPGBYYNURQR-UHFFFAOYSA-N 0.000 claims 1
- HCDLATBHMBZZNA-UHFFFAOYSA-N 8-methyl-3-(6-thiophen-2-ylpyridazin-3-yl)-3,8-diazabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CN2C(N=N1)=CC=C1C1=CC=CS1 HCDLATBHMBZZNA-UHFFFAOYSA-N 0.000 claims 1
- XZXNRTFDNADLMF-UHFFFAOYSA-N 8-methyl-3-(6-thiophen-3-ylpyridazin-3-yl)-3,8-diazabicyclo[3.2.1]octane Chemical compound CN1C(C2)CCC1CN2C(N=N1)=CC=C1C=1C=CSC=1 XZXNRTFDNADLMF-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000026097 Factitious disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010052276 Pseudodementia Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 102000034337 acetylcholine receptors Human genes 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000002920 convulsive effect Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 201000009863 inflammatory diarrhea Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 230000029849 luteinization Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- IDKMYYJLMVVTIE-UHFFFAOYSA-N n-[2-[6-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)pyridazin-3-yl]phenyl]acetamide Chemical compound CN1C(C2)CCC1CN2C(N=N1)=CC=C1C1=CC=CC=C1NC(C)=O IDKMYYJLMVVTIE-UHFFFAOYSA-N 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 230000020341 sensory perception of pain Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000016160 smooth muscle contraction Effects 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200401603 | 2004-10-20 | ||
| US62032704P | 2004-10-21 | 2004-10-21 | |
| PCT/EP2005/055333 WO2006045716A1 (en) | 2004-10-20 | 2005-10-18 | Novel diazabicyclic aryl derivatives and their medical use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008517032A JP2008517032A (ja) | 2008-05-22 |
| JP2008517032A5 true JP2008517032A5 (enExample) | 2008-12-11 |
Family
ID=38731691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007537263A Abandoned JP2008517032A (ja) | 2004-10-20 | 2005-10-18 | 新規なジアザ二環式アリール誘導体及びその医薬用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20080153806A1 (enExample) |
| EP (1) | EP1805183B1 (enExample) |
| JP (1) | JP2008517032A (enExample) |
| CN (1) | CN101035792B (enExample) |
| AT (1) | ATE493415T1 (enExample) |
| AU (1) | AU2005298693A1 (enExample) |
| CA (1) | CA2584838A1 (enExample) |
| DE (1) | DE602005025667D1 (enExample) |
| MX (1) | MX2007004269A (enExample) |
| NZ (1) | NZ553622A (enExample) |
| WO (1) | WO2006045716A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4931823B2 (ja) | 2004-10-18 | 2012-05-16 | アムジエン・インコーポレーテツド | チアジアゾール化合物及び使用方法 |
| DE602006019561D1 (de) | 2005-02-16 | 2011-02-24 | Neurosearch As | Diazabicyclische arylderivate und ihre verwendung als chinolinergische liganden an nikotin-acetylcholin-rezeptoren |
| CA2632642A1 (en) | 2005-12-06 | 2007-06-14 | Neurosearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
| EP1984365A1 (en) | 2006-02-10 | 2008-10-29 | NeuroSearch A/S | 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| WO2007090887A1 (en) | 2006-02-10 | 2007-08-16 | Neurosearch A/S | 3, 9-diazabicyclo [3.3. 1]nonane derivatives and their use as monoamine?neurotransmitter re-uptake inhibitors |
| US7687523B2 (en) | 2006-02-10 | 2010-03-30 | Neurosearch A/S | 3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists |
| WO2007093601A1 (en) | 2006-02-14 | 2007-08-23 | Neurosearch A/S | 3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives as nicotinic acetylcholine receptor agonists |
| JP2009537599A (ja) | 2006-05-23 | 2009-10-29 | ノイロサーチ アクティーゼルスカブ | 新規８，１０−ジアザ−ビシクロ［４．３．１］デカン誘導体及びそれらの医学的使用 |
| US8314119B2 (en) * | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
| US7919504B2 (en) | 2007-07-17 | 2011-04-05 | Amgen Inc. | Thiadiazole modulators of PKB |
| SA08290475B1 (ar) * | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| FR2937641A1 (fr) | 2008-10-28 | 2010-04-30 | Sanofi Aventis | Derives d'urees de tropane, leur preparation et leur application en therapeutique |
| EP2619205B1 (en) | 2010-09-23 | 2017-05-17 | AbbVie Bahamas Ltd. | Monohydrate of an azaadamantane derivative |
| FR2974365B1 (fr) * | 2011-04-20 | 2017-08-25 | Centre Nat De La Rech Scient (C N R S) | 1,2,3-triazoles 1,4-disubstituees, leurs procedes de preparation et leurs utilisations diagnostiques et therapeutiques |
| TW201311698A (zh) * | 2011-08-22 | 2013-03-16 | Targacept Inc | 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷 |
| US8729263B2 (en) * | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| JP2021521200A (ja) * | 2018-04-10 | 2021-08-26 | スカイホーク・セラピューティクス・インコーポレーテッド | 癌の処置のための化合物 |
| CN119235864A (zh) * | 2020-07-17 | 2025-01-03 | 卫材R&D管理有限公司 | 取代的哌啶化合物及其用途 |
| JP7591592B2 (ja) * | 2022-01-14 | 2024-11-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 置換ピペリジン化合物を含有する医薬 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7265115B2 (en) * | 1999-01-29 | 2007-09-04 | Abbott Laboratories | Diazabicyclic CNS active agents |
| NZ513575A (en) * | 1999-05-04 | 2003-07-25 | Neurosearch As | Heteroaryl diazabicycloalkanes useful for treating or preventing a disease or a disorder responsive to the activity of nAChR modulators |
| US20050065178A1 (en) * | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
-
2005
- 2005-10-18 AU AU2005298693A patent/AU2005298693A1/en not_active Abandoned
- 2005-10-18 EP EP05801524A patent/EP1805183B1/en not_active Expired - Lifetime
- 2005-10-18 AT AT05801524T patent/ATE493415T1/de not_active IP Right Cessation
- 2005-10-18 CA CA002584838A patent/CA2584838A1/en not_active Abandoned
- 2005-10-18 US US11/665,387 patent/US20080153806A1/en not_active Abandoned
- 2005-10-18 MX MX2007004269A patent/MX2007004269A/es active IP Right Grant
- 2005-10-18 CN CN2005800337300A patent/CN101035792B/zh not_active Expired - Fee Related
- 2005-10-18 WO PCT/EP2005/055333 patent/WO2006045716A1/en not_active Ceased
- 2005-10-18 DE DE602005025667T patent/DE602005025667D1/de not_active Expired - Lifetime
- 2005-10-18 JP JP2007537263A patent/JP2008517032A/ja not_active Abandoned
- 2005-10-18 NZ NZ553622A patent/NZ553622A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009538867A5 (enExample) | ||
| JP2008530172A5 (enExample) | ||
| JP2008530171A5 (enExample) | ||
| JP2009526814A5 (enExample) | ||
| CA2389553A1 (en) | Heteroaryl-diazabicycloalkanes | |
| RU2007139255A (ru) | Новые оксадиазольные производные и их медицинское применение | |
| JP2008539195A5 (enExample) | ||
| JP2009518357A5 (enExample) | ||
| CN100432075C (zh) | 作为烟碱样乙酰胆碱受体配体的二氮杂双环芳基衍生物 | |
| JP2009537599A5 (enExample) | ||
| CA2496585A1 (en) | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | |
| JP2009526776A5 (enExample) | ||
| EP1805183B1 (en) | Novel diazabicyclic aryl derivatives and their medical use | |
| RU2008139481A (ru) | Новые 1,4-диаза-бицикло[3.2.2]нонил-оксадиазолильные производные и их медицинское применение | |
| JP2006508109A5 (enExample) | ||
| RU2008110911A (ru) | Новые диазабициклические арильные производные и их медицинское применение | |
| JP2009538869A5 (enExample) | ||
| JP2004538268A5 (enExample) | ||
| RU2005138591A (ru) | Новые производные 8-аза-бицикло{3.2.1}октана и их применение в качестве ингибиторов обратного захвата моноаминовых нейротрансмиттеров | |
| JP2007520525A5 (enExample) | ||
| JP2009537599A (ja) | 新規８，１０−ジアザ−ビシクロ［４．３．１］デカン誘導体及びそれらの医学的使用 | |
| JP2007530635A5 (enExample) | ||
| JP2009526816A5 (enExample) | ||
| JP2005530814A5 (enExample) | ||
| JP2007538046A5 (enExample) |